Immunotherapy, which engages and harness the body’s own immune system to fight cancer, has revolutionized the field of oncology. Among the most promising immunotherapy approaches are immune checkpoint blockade, adoptive cell therapies, therapeutic vaccines, oncolytic viruses, and mono, bi and trispecific antibodies. These approaches all seek to elicit a T-cell-based immune response against tumor antigens, whether endogenous or engineered, though each approach utilizes a different mechanism of action to induce this response.
In this white paper, we explore advances in cancer immunotherapy, highlighting recent progress and discussing innovative strategies for optimizing the efficacy of existing therapeutics as both single agents and combination therapies.